סינגיס ישראל - עברית - Ministry of Health

סינגיס

astrazeneca (israel) ltd - palivizumab - תמיסה להזרקה - palivizumab 100 mg/ml - palivizumab

אבוסינאגיס 100 מ"ג ישראל - עברית - Ministry of Health

אבוסינאגיס 100 מ"ג

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

אבוסינאגיס 50 מ"ג ישראל - עברית - Ministry of Health

אבוסינאגיס 50 מ"ג

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

לוסנטיס ישראל - עברית - Ministry of Health

לוסנטיס

novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).

זולאייר   150 מג ישראל - עברית - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

אקטמרה 20 מגמל I.V. ישראל - עברית - Ministry of Health

אקטמרה 20 מגמל i.v.

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

טייסברי ישראל - עברית - Ministry of Health

טייסברי

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

אקטמרה 162 מג S.C. ישראל - עברית - Ministry of Health

אקטמרה 162 מג s.c.

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

אייליה ישראל - עברית - Ministry of Health

אייליה

bayer israel ltd - aflibercept - תמיסה להזרקה לזגוגית העין - aflibercept 40 mg/ml - aflibercept

קימריה ישראל - עברית - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel